

REMARKS


Applicants have amended the specification and the claims for the sake of clarification or to correct inadvertent typographical errors made therein. All amendments are reflected in the Amendment to the Specification section (see page 2) and in the Amendment to the Claims section (see pages 3 to 6). No new matter has been added to the claims or specification by the amendment. Support for all amendments are found in the originally filed claims and specification.

In view of the above amendments and remarks, applicant believes that the claims of the present application are in condition for allowance and is earnestly solicited .

If any additional fees or charges are required authorization is hereby granted to charge any necessary fees to Deposit Account No. 19-2570 accordingly.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number below.

Respectfully submitted,


Grace C. Hsu
Attorney for Applicants
Registration No. 51,336

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Telephone: (610) 270-4650
Facsimile: (610) 270-5073

n:\mtf\P51365PreliminaryAmendment

10/518654

ABSTRACT OF THE DISCLOSURE

DT01 Rec'd PCT/PTC 16 DEC 2004

The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.